A Clinical-Stage Oncology Company Advancing a Differentiated Approach to Cancer.
Advancing Telomir-Zn with an FDA-cleared IND for a Phase 1/2 study in advanced or metastatic triple-negative breast cancer (TNBC).
Investment Highlights
A major unmet need in TNBC.
TNBC lacks the key receptors that guide treatment in other major breast cancers, and many patients still face limited options and treatment resistance.
A mechanistically distinct approach.
Telomir-Zn targets iron-dependent KDM enzymes implicated in epigenetic silencing, offering a differentiated approach to cancer biology.
An important clinical milestone achieved.
FDA clearance of the IND enables initiation of a Phase 1/2 study in advanced or metastatic TNBC.
Worldwide rights to Telomir-Zn.
Telomir holds exclusive worldwide rights to Telomir-Zn across indications, providing control over development, regulatory strategy, and potential commercialization.
A significant market opportunity.
TNBC represents a multi-billion-dollar global treatment market with persistent unmet need, particularly in advanced and metastatic disease.
Latest News
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
View Press Release
Latest
Presentation
Upcoming Events
October 7, 2026 12:00 AM ETBioJapan
You are about to review presentations, reports and/or filings of Telomir Pharmaceuticals, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Telomir Pharmaceuticals, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Telomir Pharmaceuticals, Inc.